Ionis Pharmaceuticals
OverviewSuggest Edit
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. It provides an antisense technology platform designed to treat complicated and rare diseases. The company offers SPINRAZA, a treatment for children and adults with spinal muscular atrophy (SMA), TEGSEDI, a medicine that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, and Waylivra, a medicine used to treat familial chylomicronaemia syndrome (FCS).
| Type | Public | |
| Founded | 1989 | |
| HQ | Carlsbad, CA, US | Map |
| Website | ionispharma.com | |
| Employee Ratings | More | |
| Overall Culture | D- | More |
Recent NewsAll News
- Global RNAi Therapeutics Market Research Report 2022: A Concentrated Market - Key Players are Moderna, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Silence Therapeutics
- What’s Next For Ionis Pharmaceuticals Stock After A 14% Fall?
- Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology
- Ionis Pharmaceuticals Stock Looks Attractive At $37
Key People/Management at Ionis Pharmaceuticals
Brett P. Monia
Chief Executive Officer, Director
Onaiza Cadoret-Manier
Executive Vice President, Chief Product Strategy and Operations Officer
C. Frank Bennett
Executive Vice President, Chief Scientific Officer
Eric E. Swayze
Executive Vice President, Research
Richard S. Geary
Executive Vice President, Chief Development Officer
Patrick R. O'Neil
Chief Legal Officer and General Counsel
Ionis Pharmaceuticals Office Locations
Ionis Pharmaceuticals has an office in Carlsbad
Carlsbad, CA, US (HQ)
2855 Gazelle Ct
Ionis Pharmaceuticals Financials and Metrics
Ionis Pharmaceuticals Revenue
Ionis Pharmaceuticals's revenue was reported to be $729.26 m in FY, 2020 which is a 35% decrease from the previous period.
| USD | |
|---|---|
Revenue (Q1, 2021) | 111.6m |
Gross profit (Q1, 2021) | 109.0m |
Gross profit margin (Q1, 2021), % | 97.7% |
Net income (Q1, 2021) | (89.9m) |
EBIT (Q1, 2021) | (92.0m) |
Market capitalization (25-May-2022) | 5.3b |
Closing stock price (25-May-2022) | 36.9 |
Cash (31-Mar-2021) | 414.2m |
EV | 5.0b |
Ionis Pharmaceuticals's current market capitalization is $5.3 b.
Annual
Annual
Annual
Quarterly
| USD | FY, 2018 |
|---|---|
Revenue/Employee | 1.1m |
Debt/Equity | 0.5 x |
Debt/Assets | 0.2 x |
Financial Leverage | 2.2 x |
Ionis Pharmaceuticals Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Akcea Therapeutics | August 31, 2020 | $500 m |
| Akcea Securities Corporation | ||
| Akcea Therapeutics Canada Inc | ||
| Akcea Therapeutics France SAS | ||
| Akcea Therapeutics Germany GmbH | ||
| Akcea Therapeutics, Inc | ||
| Akcea Therapeutics Ireland Limited | ||
| Akcea Therapeutics UK Limited | ||
| Ionis Development (Ireland) Limited | ||
| Isis USA Limited |
Ionis Pharmaceuticals Revenue Breakdown
Ionis Pharmaceuticals revenue breakdown by business segment: 19.6% from Akcea Therapeutics and 80.4% from Ionis Core
Ionis Pharmaceuticals Cybersecurity Score
Ionis Pharmaceuticals Environment, Social & Governance (ESG) Ratings
Ionis Pharmaceuticals Online and Social Media Presence
3.96k Twitter followers
Ionis Pharmaceuticals has 3.96k Twitter Followers. The number of followers has increased 1.4% month over month and increased 3.7% quarter over quarter
Ionis Pharmaceuticals's Trends
Twitter Engagement Stats for @ionispharma
1.1k
Tweets
504
Following
4k
Followers
8
Tweets last 30 days
3.3
Avg. likes per Tweet
100%
Tweets with engagement
Ionis Pharmaceuticals Company Culture
Overall Culture
D-
56/100
CEO Rating
F
53/100
Compensation
C-
62/100
Diversity
D
60/100
Ionis Pharmaceuticals News and Updates
April 07, 2022
Global RNAi Therapeutics Market Research Report 2022: A Concentrated Market - Key Players are Moderna, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Silence Therapeutics
DUBLIN, April 7, 2022 /PRNewswire/ -- The "Global RNAi Therapeutics Market: Analysis By Molecule Type, By Application, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering. The report provides an in-depth...
October 20, 2021
What’s Next For Ionis Pharmaceuticals Stock After A 14% Fall?
The stock price of Ionis Pharmaceuticals, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, plunged 14% in yesterday’s trade to its five year low levels of $30, while it is down 19% over the last one month...
July 13, 2021
Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ: BCYC) to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense (LICA) medicines.
June 23, 2021
Ionis Pharmaceuticals Stock Looks Attractive At $37
We believe that the stock price of Ionis Pharmaceuticals, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, is undervalued at current levels of under $37. IONS stock is down 11% from the levels of around $42 it was at on March 23, 2020...
June 03, 2021
Ionis Pharmaceuticals (IONS) Names Joseph Loscalzo Chairman, Allene Diaz Appointed Director
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced changes to its board of directors. Joseph Loscalzo, M.D., Ph.D., has been appointed chairman of the board and Allene M. Diaz has been appointed to the board.
May 14, 2021
SVB Leerink Boosts Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $41.00
Ionis Pharmaceuticals (NASDAQ:IONS) had its target price lifted by equities researchers at SVB Leerink from $36.00 to $41.00 in a research note issued on Friday, Benzinga reports. The firm currently has a "market perform" rating on the stock. SVB Leerink's target price points to a potential upside o…
Ionis Pharmaceuticals Blogs
May 12, 2022
Ionis to present at RBC Capital Markets Global Healthcare Conference
CARLSBAD, Calif. , May 12, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022 . A live webcast and additional information about this presentation can be
May 02, 2022
Ionis to host 2022 virtual Annual Meeting of Stockholders
CARLSBAD, Calif. , May 2, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2022 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 2, 2022 . The agenda for the event is as follows: -
April 20, 2022
Ionis to hold first quarter 2022 financial results webcast
Ionis to hold first quarter 2022 financial results webcast
Content Import
Wed, 04/20/2022 - 07:07
Ionis to hold first quarter 2022 financial results webcast
April 20, 2022 at 7:05 AM EDT
General
Webcast scheduled for Wednesday, May 4 at 11:30 a.m. …
April 04, 2022
Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session
Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session
william.meady@…
Mon, 04/04/2022 - 00:16
Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at…
March 16, 2022
Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine
Treatment with donidalorsen in Phase 2 study significantly reduced angioedema attacks by 90% and provided improvement in quality of life Published findings demonstrate favorable safety and tolerability profile of donidalorsen in Phase 2 study Donidalorsen is one of Ionis’ wholly owned medicines the
March 07, 2022
Ionis calls for applications for Janice Wiesman Young Investigator Grant Program
- $50,000 grant will fund research and understanding of transthyretin amyloidosis CARLSBAD, Calif. , March 7, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced it is now accepting applications for the Janice Wiesman Young Investigator Grant Program , which honors
Ionis Pharmaceuticals Frequently Asked Questions
When was Ionis Pharmaceuticals founded?
Ionis Pharmaceuticals was founded in 1989.
Who are Ionis Pharmaceuticals key executives?
Ionis Pharmaceuticals's key executives are Brett P. Monia, Onaiza Cadoret-Manier and C. Frank Bennett.
How many employees does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 757 employees.
What is Ionis Pharmaceuticals revenue?
Latest Ionis Pharmaceuticals annual revenue is $729.3 m.
What is Ionis Pharmaceuticals revenue per employee?
Latest Ionis Pharmaceuticals revenue per employee is $963.4 k.
Who are Ionis Pharmaceuticals competitors?
Competitors of Ionis Pharmaceuticals include Lannett, Intellia Therapeutics and Ultragenyx Pharmaceutical.
Where is Ionis Pharmaceuticals headquarters?
Ionis Pharmaceuticals headquarters is located at 2855 Gazelle Ct, Carlsbad.
Where are Ionis Pharmaceuticals offices?
Ionis Pharmaceuticals has an office in Carlsbad.
How many offices does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies